NovaBay Pharmaceuticals Stock

Equities

NBY

US66987P3001

Market Closed - Nyse 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.0788 USD +2.34% Intraday chart for NovaBay Pharmaceuticals +8.69% -61.37%
Sales 2024 * 14.8M Sales 2025 * 19.28M Capitalization 2.78M
Net income 2024 * -3M Net income 2025 * - EV / Sales 2024 * 0.19 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.14 x
P/E ratio 2024 *
-0.29 x
P/E ratio 2025 *
3.08 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc.. CI
NovaBay Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2023 CI
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. for $1.07 million. CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Transcript : NovaBay Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $3.3M, vs. Street Est of $3.55M MT
Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft CI
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft MT
NovaBay Pharmaceuticals, Inc. Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova®? Allograft CI
More news
1 day+2.34%
1 week+8.69%
Current month-24.74%
1 month-29.14%
3 months-56.17%
6 months-77.28%
Current year-61.37%
More quotes
1 week
0.07
Extreme 0.065
0.09
1 month
0.07
Extreme 0.065
0.11
Current year
0.07
Extreme 0.065
0.24
1 year
0.07
Extreme 0.065
1.28
3 years
0.07
Extreme 0.065
30.70
5 years
0.07
Extreme 0.065
141.40
10 years
0.07
Extreme 0.065
1 137.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 13-01-31
Director of Finance/CFO 38 19-11-30
Members of the board TitleAgeSince
Chairman 89 02-04-30
Director/Board Member 67 19-09-10
Director/Board Member 49 16-01-25
More insiders
Date Price Change Volume
24-04-25 0.077 -0.39% 528,596
24-04-24 0.0773 +0.39% 1,017,592
24-04-23 0.077 +6.21% 1,571,117
24-04-22 0.0725 -12.01% 4,146,227
24-04-19 0.0824 -1.90% 1,715,039

Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT

More quotes
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells consumer products for the eyecare and skincare markets. The Company's lead product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have antimicrobial properties as it removes foreign material, such as microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with its form of hypochlorous acid and is cleared by the United States Food and Drug Administration (FDA) for sale in the United States. Its other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress and the i-Chek. Avenova Spray is available both over-the-counter and as a prescription. Avenova Spray is also available at optometrists and ophthalmologists offices; at national pharmacy chains across all over 50 states, and through its Partner Pharmacy Program.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.077 USD
Average target price
2.6 USD
Spread / Average Target
+3,276.62%
Consensus